EyePoint Pharmaceuticals - EYPT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.57
  • Forecasted Upside: 246.22%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$8.83
▲ +0.59 (7.16%)

This chart shows the closing price for EYPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New EyePoint Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EYPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EYPT

Analyst Price Target is $30.57
▲ +246.22% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $30.57, with a high forecast of $44.00 and a low forecast of $15.00. The average price target represents a 246.22% upside from the last price of $8.83.

This chart shows the closing price for EYPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in EyePoint Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/11/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/28/2024Jefferies Financial GroupInitiated CoverageBuy$15.00
8/13/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$32.00 ➝ $29.00
6/28/2024Chardan CapitalReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
6/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
6/4/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$35.00 ➝ $32.00
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$33.00 ➝ $30.00
5/8/2024Robert W. BairdLower TargetOutperform ➝ Outperform$46.00 ➝ $38.00
5/7/2024Chardan CapitalLower TargetBuy ➝ Buy$39.00 ➝ $28.00
5/7/2024MizuhoLower TargetBuy ➝ Buy$39.00 ➝ $30.00
2/16/2024Capital One FinancialReiterated RatingOverweight
2/16/2024MizuhoBoost TargetBuy ➝ Buy$30.00 ➝ $39.00
1/22/2024JPMorgan Chase & Co.Initiated CoverageOverweight$35.00
1/16/2024HC WainwrightLower TargetBuy ➝ Buy$35.00 ➝ $33.00
12/11/2023Capital One FinancialInitiated CoverageOverweight$44.00
12/7/2023MizuhoBoost TargetBuy ➝ Buy$20.00 ➝ $30.00
12/5/2023HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $35.00
11/2/2023HC WainwrightLower TargetBuy ➝ Buy$27.00 ➝ $25.00
11/2/2023MizuhoInitiated CoverageBuy$20.00
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$31.00
9/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$31.00
8/3/2023Chardan CapitalReiterated RatingBuy ➝ Buy$22.00
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
7/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
5/19/2023HC WainwrightBoost Target$25.00 ➝ $27.00
5/18/2023Chardan CapitalBoost Target$21.00 ➝ $22.00
4/20/2023Robert W. BairdInitiated CoverageOutperform$33.00
3/27/2023HC WainwrightReiterated RatingBuy$25.00
3/3/2023Chardan CapitalReiterated RatingBuy$21.00
2/28/2023HC WainwrightReiterated RatingBuy$25.00
11/11/2022GuggenheimLower TargetBuy$60.00 ➝ $52.00
8/4/2022HC WainwrightBoost Target$24.00 ➝ $25.00
8/2/2022HC WainwrightReiterated RatingBuy$24.00
7/7/2022Chardan CapitalInitiated CoverageBuy$21.00
3/4/2022Cantor FitzgeraldReiterated RatingOverweight
3/4/2022HC WainwrightReiterated RatingBuy$24.00
11/15/2021CowenBoost TargetOutperform$25.00 ➝ $35.00
11/15/2021HC WainwrightReiterated RatingBuy$15.00 ➝ $24.00
10/13/2021HC WainwrightReiterated RatingBuy$15.00
7/21/2021HC WainwrightReiterated RatingBuy$15.00
7/9/2021HC WainwrightReiterated RatingBuy$15.00
7/2/2021HC WainwrightReiterated RatingBuy$15.00
5/26/2021HC WainwrightReiterated RatingBuy$15.00
5/6/2021HC WainwrightLower TargetBuy$16.00 ➝ $15.00
3/1/2021CowenInitiated CoverageOutperform$25.00
1/29/2021HC WainwrightReiterated RatingBuy$16.00
1/27/2021Cantor FitzgeraldInitiated CoverageOverweight$22.00
1/12/2021B. RileyBoost TargetBuy$5.00 ➝ $8.50
10/9/2020HC WainwrightUpgradeNeutral ➝ Buy$200.00
8/6/2020HC WainwrightReiterated RatingHold
4/6/2020B. RileyDowngradeBuy ➝ Neutral$400.00 ➝ $100.00
4/2/2020HC WainwrightReiterated RatingHold
3/3/2020HC WainwrightReiterated RatingHold
2/4/2020HC WainwrightReiterated RatingHold
1/24/2020HC WainwrightReiterated RatingHold
11/11/2019HC WainwrightDowngradeBuy ➝ Neutral
11/5/2019HC WainwrightReiterated RatingBuy$450.00
11/4/2019LaidlawInitiated CoverageBuy$500.00
(Data available from 10/12/2019 forward)

News Sentiment Rating

1.15 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 17 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/16/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 14 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/15/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/14/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/14/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/13/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/12/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/12/2024

Current Sentiment

  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
EyePoint Pharmaceuticals logo
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $8.83
Low: $8.20
High: $8.90

50 Day Range

MA: $8.50
Low: $7.58
High: $9.30

52 Week Range

Now: $8.83
Low: $5.67
High: $30.99

Volume

716,769 shs

Average Volume

923,145 shs

Market Capitalization

$459.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of EyePoint Pharmaceuticals?

The following Wall Street analysts have issued reports on EyePoint Pharmaceuticals in the last year: Cantor Fitzgerald, Capital One Financial Co., Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Robert W. Baird, and StockNews.com.
View the latest analyst ratings for EYPT.

What is the current price target for EyePoint Pharmaceuticals?

7 Wall Street analysts have set twelve-month price targets for EyePoint Pharmaceuticals in the last year. Their average twelve-month price target is $30.57, suggesting a possible upside of 246.2%. Capital One Financial Co. has the highest price target set, predicting EYPT will reach $44.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $15.00 for EyePoint Pharmaceuticals in the next year.
View the latest price targets for EYPT.

What is the current consensus analyst rating for EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EYPT will outperform the market and that investors should add to their positions of EyePoint Pharmaceuticals.
View the latest ratings for EYPT.

What other companies compete with EyePoint Pharmaceuticals?

How do I contact EyePoint Pharmaceuticals' investor relations team?

EyePoint Pharmaceuticals' physical mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company's listed phone number is (617) 926-5000 and its investor relations email address is [email protected]. The official website for EyePoint Pharmaceuticals is eyepointpharma.com. Learn More about contacing EyePoint Pharmaceuticals investor relations.